Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Change in Receivables (2016 - 2025)

Traws Pharma's Change in Receivables history spans 12 years, with the latest figure at $1.8 million for Q4 2025.

  • Quarterly results put Change in Receivables at $1.8 million for Q4 2025, up 606.46% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (up 671.55% YoY), and the annual figure for FY2025 was $2.0 million, up 16.14%.
  • Change in Receivables for Q4 2025 was $1.8 million at Traws Pharma, up from $668000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.8 million in Q4 2025 to a low of -$356000.0 in Q4 2024.
  • The 5-year median for Change in Receivables is -$1000.0 (2021), against an average of $137666.7.
  • The sharpest move saw Change in Receivables crashed 1100.0% in 2023, then skyrocketed 606.46% in 2025.
  • Year by year, Change in Receivables stood at -$1000.0 in 2021, then changed by 0.0% to -$1000.0 in 2022, then soared by 200.0% to $1000.0 in 2023, then tumbled by 35700.0% to -$356000.0 in 2024, then skyrocketed by 606.46% to $1.8 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $1.8 million, $668000.0, and -$331000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.